Ready for a Power Move? 🚀

Real-time trading, streaming charts, market analysis, and penny stock scanners.

Yeah, that’s right, and it’s available to you RIGHT NOW at no additional cost.

Market Master’s trading room, where our top traders share market insight and live trade ideas daily. 

Jump in right here and take a look for yourself!

Good morning!

I’m riding high after yesterday’s special “tactical trade” idea to my mobile alerts list surged as high as 40% multiple times before closing up 31% (and it’s moving even higher in the premarket as of this writing).

It was a top-10 mover in the entire market yesterday morning:

That was right on the heels of last week’s “tactical” idea that also jumped over 40% after I brought it to readers’ attention:

With stock futures trading slightly down and Bloomberg reporting that “Stocks Fluctuate as Traders Track Rush of Earnings,” I’m once again turning to a small-cap idea that I think has a good chance of a surge.

Go ahead and pull up OKYO Pharma Limited (OKYO) on your trading platform.

You’ll see that the stock has been relatively stable over the last three months, other than a brief 40% spike in late August…

Notice it has had very reliable support around the $1.00 mark since early August.

I’ve discussed this before, but I really like small-cap stocks with support at this price range due to Nasdaq’s Minimum Bid Price requirement.

If you aren’t familiar with that, it’s a rule that says a stock must not close below $1.00 for 30 trading days or it falls out of compliance.

As a result, companies listed on the Nasdaq — and their investors — tend to fight hard to stay above that range.

I can’t say for certain, but that may be why OKYO has had such a firm base of support there.

I also like that OKYO had a 4% jump yesterday, even as the broader markets were essentially flat.

I think it’s definitely worth taking a good look at the stock at this level, but if it closes below $.90, I would consider the support broken…

On the upside, though, if it breaks $1.10 today, we could be looking at a much bigger breakout.

Make sure OKYO is on the top of your watchlist today.

In the meantime, here are some notes from my research about this interesting company…

To begin with, OKYO has an excellent website.

I’ve studied perhaps hundreds of clinical-stage biopharma company websites, and they often get so bogged down in complex science that I don’t see how they expect ordinary investors to understand their pipeline.

Maybe that’s their goal??

OKYO, on the other hand, does a great job of explaining their science, leadership, and investment opportunity.

The company’s main target is Dry Eye Disease (DED), which has a multibillion-dollar market (who knew? 🤷).

DED results when the eyes don’t produce enough tears, causing poor lubrication that can lead to redness, grittiness, burning, blurring, and eye fatigue.

The condition is surprisingly prevalent, with approximately 38 million cases in the US and 700 million cases worldwide.

It affects over 35% of the population aged 50+ and two-thirds of DED patients are women.

The company’s lead candidate is OK-101, a topical drug designed to control inflammation and pain in the eye.

The company has been progressing the drug rapidly. 

It began a Phase 2 trial for OK-101 as a treatment for DED in May 2023 and revealed ”extremely encouraging” topline data from the trial in January this year.

The trial found that OK-101 had a “highly favorable tolerability profile” and achieved statistical significance for multiple “sign” and “symptom” endpoints.

Specifically, the drug proved superior to the placebo for “total conjunctival staining” — a sign of DED — and for burning/stinging and blurred vision.

The company said that “To our knowledge, there are no FDA approved DED drugs that have been shown in clinical studies to improve conjunctival staining.”

OKYO now plans to advance OK-101 to a Phase 3 trial with the goal of developing a “highly differentiated dry eye product to help patients underserved by current treatments.”

In the course of the Phase 2 trial, researchers also found support for the potential of OK-101 to treat neuropathic corneal pain (NCP) — “a severe, chronic, and debilitating disease for which there are no approved commercial treatments currently available” and that affects approximately 5 million people each year.

OKYO is pursuing a parallel development focus of OK-101 for that disease.

In February, the FDA “cleared OK-101 as its first Investigational New Drug (IND) application for the treatment of NCP” [emphasis added] and OKYO began a Phase II trial for that purpose just last week.

The principal investigator of the trial is Pedram Hamrah, MD, of Tufts Medical Center — a renowned expert in NCP.

OKYO insiders have been scooping up shares rapidly, with executive chairman Gabriele Cerrone — a veteran of micro-cap biotechs — purchasing 50,000 shares in September, bringing his total ownership to 29% of issued share capital.

The sole analyst covering OKYO last week reiterated a 12-month price target of $7.00 — a nearly 600% increase over the stock’s current price.

For your own research, I recommend starting with an excellent August interview with OKYO CEO Gary Jacob, Ph.D. And of course be sure to check out the company’s website and corporate presentation.

Always be sure to approach your trading in a responsible manner. Trading is very risky, and nothing is ever guaranteed, so never trade with more than you can afford to lose. Please read the full disclaimer at the bottom of this email as well so you are aware of additional risks and considerations. Always have a well-thought-out game plan that takes your personal risk tolerance into consideration.

Bottom line: I like the firm support OKYO has found at the $1.00 level, and it is rapidly pursuing development of OK-101 with great preliminary data supporting it.

We could see a significant breakout on OKYO today, especially if it pushes above the $1.10 level, so pay close attention and keep it at the top of your radar today.

To Your Success,

Jeff Bishop

P.S. Make sure you join me and over 1000 traders in the Market Master’s trading roomtoday for live trading signals and education. You can access it at no cost right now.

Questions or concerns about our products? Email [email protected] © Copyright 2022, RagingBull

*Issuer-paid advertisement:  Just so you know, what you're reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let's be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren't what you'd call “typical.”

Just a quick heads up about this ad you're reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we have 

been paid twenty five thousand dollars (cash) by bank transfer by OKYO Pharma Limited for advertising for a one day marketing program on October 23, 2024.  Be aware that we may also buy or sell shares in the company at some point in the future, although neither RagingBull nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as our program ends, though that is not always the case.

Now, diving right into OKYO Pharma Limited might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there's exceptional risk involved in trading. This isn't small potatoes we're talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We're shining a light on the good stuff about the company here, but it's on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r.

Oh, that brings us to another crucial point—we're not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now.

Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can't wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who's licensed to give you real advice. To be clear, 

Neither Raging Bull nor its owners, employees, or independent contractors are registered as a secur1ties br0ker-dealer, br0ker, 1nvestment advis0r (IA), or IA rep’s with the SEC, any state securities regulat0ry authority, or any self-regulat0ry organization.

So, that's the scoop! If you're intrigued and want to learn more about the companies we talk about, hit up the SEC's website to dig into their filings and see the full picture.